Could Pfizer Have an Ozempic Killer on the Way?
An Ozempic craze has swept across the United States. So many prescriptions were written for the type 2 diabetes drug marketed by Novo Nordisk (NYSE: NVO) that supplies weren't enough to meet the demand in late 2022.
It wasn't because so many patients were newly diagnosed with type 2 diabetes. Instead, Ozempic gained widespread popularity for helping people lose weight.
A sibling product, Wegovy, a higher-dose version of the active ingredient in Ozempic that is actually approved for weight loss, has flown off pharmacies' shelves as well. Unsurprisingly, Novo Nordisk's market cap has soared close to 40% over the past 12 months.
Source Fool.com
